BGI Genomics
RU-friendlyChina's genomics powerhouse — CRISPR-based diagnostics kits, DNBSEQ sequencing for pathogen identification, and large-scale COVID diagnostics infrastructure deployed in 80+ countries.
- Country
- China
- Revenue
- CNY 3B
- Employees
- ~10,000 emp
ISO 13485
CE-IVD
NMPA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | — | ✓ |
| cross-sector-intersections | ✓ | ✓ | ✓ | ✓ |
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| ecosystem-restoration | ✓ | ✓ | ✓ | ✓ |
| finance-investment | ✓ | ✓ | — | ✓ |
| foundries-design | ✓ | ✓ | — | ✓ |
| monitoring-conservation | ✓ | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | — | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpausda-aphismoa-chinaefsaepaademe
Technologies
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.